多模式癌胚抗原靶向荧光和放射引导下的细胞减少手术治疗结肠直肠腹膜转移:单臂验证性试验。

IF 3.5 3区 医学 Q1 SURGERY
BJS Open Pub Date : 2025-03-04 DOI:10.1093/bjsopen/zraf045
Aaya Darai, Jan Marie de Gooyer, Sander Ubels, Andreas J A Bremers, Philip R de Reuver, Erik H J G Aarntzen, Iris D Nagtegaal, Mark Rijpkema, Johannes H W de Wilt
{"title":"多模式癌胚抗原靶向荧光和放射引导下的细胞减少手术治疗结肠直肠腹膜转移:单臂验证性试验。","authors":"Aaya Darai, Jan Marie de Gooyer, Sander Ubels, Andreas J A Bremers, Philip R de Reuver, Erik H J G Aarntzen, Iris D Nagtegaal, Mark Rijpkema, Johannes H W de Wilt","doi":"10.1093/bjsopen/zraf045","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Selection of suitable candidates for intraoperative tumour detection and cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is important for improving outcomes for patients with colorectal peritoneal metastases. Previous research demonstrated the use of single-photon emission computed tomography (SPECT), intraoperative radiodetection, and near-infrared fluorescence (NIRF)-guided surgery with a dual-labelled 111In-labelled dodecane tetra-acetic acid (DOTA)-labetuzumab-IRDye800CW tracer to detect peritoneal metastases before operation. The aim of this study was to validate these results.</p><p><strong>Methods: </strong>A single-centre phase II study was conducted to evaluate the safety and feasibility of 111In-labelled DOTA-labetuzumab-IRDye800CW in patients with colorectal peritoneal metastases undergoing CRS-HIPEC. SPECT/computed tomography (CT) was undertaken before surgery, after intravenous administration of 10 mg 111In-labelled DOTA-labetuzumab-IRDye800CW (mean 101.25 MBq). During surgery, radiodetection and NIRF imaging were used for tumour detection. Adverse events were assessed, and tumour-to-background ratios (TBRs) and peritoneal cancer index scores were analysed.</p><p><strong>Results: </strong>Seven patients were included. No study-related severe adverse events were reported. Imaging before surgery revealed previously undetected metastases in one patient. The mean(standard deviation, s.d.) SPECT/CT peritoneal cancer index score was 3(2), and the intraoperative score was 14(7) (P = 0.032). A total of 52 lesions were removed during CRS, of which 37 were malignant. With NIRF imaging, 34 (92%) of 37 malignant lesions were detectable. Of 52 fluorescent lesions, 4 were false-positive. Mean(s.d.) fluorescence TBR was 3.4(1.8) and mean radiodetection TBR was 4.4(1.4).</p><p><strong>Conclusion: </strong>This study confirmed the safety and feasibility of multimodal image-guided surgery in patients with peritoneal metastases.</p>","PeriodicalId":9028,"journal":{"name":"BJS Open","volume":"9 2","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12018875/pdf/","citationCount":"0","resultStr":"{\"title\":\"Multimodal carcinoembryonic antigen-targeted fluorescence and radio-guided cytoreductive surgery for peritoneal metastases of colorectal origin: single-arm confirmatory trial.\",\"authors\":\"Aaya Darai, Jan Marie de Gooyer, Sander Ubels, Andreas J A Bremers, Philip R de Reuver, Erik H J G Aarntzen, Iris D Nagtegaal, Mark Rijpkema, Johannes H W de Wilt\",\"doi\":\"10.1093/bjsopen/zraf045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Selection of suitable candidates for intraoperative tumour detection and cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is important for improving outcomes for patients with colorectal peritoneal metastases. Previous research demonstrated the use of single-photon emission computed tomography (SPECT), intraoperative radiodetection, and near-infrared fluorescence (NIRF)-guided surgery with a dual-labelled 111In-labelled dodecane tetra-acetic acid (DOTA)-labetuzumab-IRDye800CW tracer to detect peritoneal metastases before operation. The aim of this study was to validate these results.</p><p><strong>Methods: </strong>A single-centre phase II study was conducted to evaluate the safety and feasibility of 111In-labelled DOTA-labetuzumab-IRDye800CW in patients with colorectal peritoneal metastases undergoing CRS-HIPEC. SPECT/computed tomography (CT) was undertaken before surgery, after intravenous administration of 10 mg 111In-labelled DOTA-labetuzumab-IRDye800CW (mean 101.25 MBq). During surgery, radiodetection and NIRF imaging were used for tumour detection. Adverse events were assessed, and tumour-to-background ratios (TBRs) and peritoneal cancer index scores were analysed.</p><p><strong>Results: </strong>Seven patients were included. No study-related severe adverse events were reported. Imaging before surgery revealed previously undetected metastases in one patient. The mean(standard deviation, s.d.) SPECT/CT peritoneal cancer index score was 3(2), and the intraoperative score was 14(7) (P = 0.032). A total of 52 lesions were removed during CRS, of which 37 were malignant. With NIRF imaging, 34 (92%) of 37 malignant lesions were detectable. Of 52 fluorescent lesions, 4 were false-positive. Mean(s.d.) fluorescence TBR was 3.4(1.8) and mean radiodetection TBR was 4.4(1.4).</p><p><strong>Conclusion: </strong>This study confirmed the safety and feasibility of multimodal image-guided surgery in patients with peritoneal metastases.</p>\",\"PeriodicalId\":9028,\"journal\":{\"name\":\"BJS Open\",\"volume\":\"9 2\",\"pages\":\"\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-03-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12018875/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BJS Open\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/bjsopen/zraf045\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJS Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/bjsopen/zraf045","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

摘要

背景:选择合适的候选人进行术中肿瘤检测和细胞减少手术(CRS)联合腹腔热化疗(HIPEC)对改善结直肠腹膜转移患者的预后非常重要。先前的研究表明,术前使用单光子发射计算机断层扫描(SPECT),术中放射检测和近红外荧光(NIRF)引导的双标记111in标记十二烷四乙酸(DOTA)-labetuzumab-IRDye800CW示踪剂检测腹膜转移。本研究的目的是验证这些结果。方法:通过一项单中心II期研究来评估111in标记的DOTA-labetuzumab-IRDye800CW在接受CRS-HIPEC的结直肠腹膜转移患者中的安全性和可行性。术前静脉给药10mg 111in标记的DOTA-labetuzumab-IRDye800CW(平均101.25 MBq)后进行SPECT/ CT检查。术中采用放射检测和NIRF成像进行肿瘤检测。评估不良事件,分析肿瘤与背景比(TBRs)和腹膜癌指数评分。结果:纳入7例患者。没有研究相关的严重不良事件的报道。术前影像学显示一名患者有先前未发现的转移。平均值(标准差,s.d.)SPECT/CT腹膜癌指数评分为3(2)分,术中评分为14(7)分(P = 0.032)。CRS期间共切除52个病灶,其中37个为恶性。在NIRF成像中,37个恶性病变中有34个(92%)被检测到。52个荧光病变中,4个为假阳性。平均(s.d)荧光TBR为3.4(1.8),平均放射检测TBR为4.4(1.4)。结论:本研究证实了多模态图像引导手术治疗腹膜转移的安全性和可行性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Multimodal carcinoembryonic antigen-targeted fluorescence and radio-guided cytoreductive surgery for peritoneal metastases of colorectal origin: single-arm confirmatory trial.

Background: Selection of suitable candidates for intraoperative tumour detection and cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is important for improving outcomes for patients with colorectal peritoneal metastases. Previous research demonstrated the use of single-photon emission computed tomography (SPECT), intraoperative radiodetection, and near-infrared fluorescence (NIRF)-guided surgery with a dual-labelled 111In-labelled dodecane tetra-acetic acid (DOTA)-labetuzumab-IRDye800CW tracer to detect peritoneal metastases before operation. The aim of this study was to validate these results.

Methods: A single-centre phase II study was conducted to evaluate the safety and feasibility of 111In-labelled DOTA-labetuzumab-IRDye800CW in patients with colorectal peritoneal metastases undergoing CRS-HIPEC. SPECT/computed tomography (CT) was undertaken before surgery, after intravenous administration of 10 mg 111In-labelled DOTA-labetuzumab-IRDye800CW (mean 101.25 MBq). During surgery, radiodetection and NIRF imaging were used for tumour detection. Adverse events were assessed, and tumour-to-background ratios (TBRs) and peritoneal cancer index scores were analysed.

Results: Seven patients were included. No study-related severe adverse events were reported. Imaging before surgery revealed previously undetected metastases in one patient. The mean(standard deviation, s.d.) SPECT/CT peritoneal cancer index score was 3(2), and the intraoperative score was 14(7) (P = 0.032). A total of 52 lesions were removed during CRS, of which 37 were malignant. With NIRF imaging, 34 (92%) of 37 malignant lesions were detectable. Of 52 fluorescent lesions, 4 were false-positive. Mean(s.d.) fluorescence TBR was 3.4(1.8) and mean radiodetection TBR was 4.4(1.4).

Conclusion: This study confirmed the safety and feasibility of multimodal image-guided surgery in patients with peritoneal metastases.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BJS Open
BJS Open SURGERY-
CiteScore
6.00
自引率
3.20%
发文量
144
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信